Study Of Abraxane® And Carboplatin As First-Line Treatment For Triple Negative Metastatic Breast Cancer

This study has been terminated.
(Low enrollment and there is insufficient data to publish.)
Sponsor:
Collaborator:
Celgene Corporation
Information provided by (Responsible Party):
Duke University
ClinicalTrials.gov Identifier:
NCT01207102
First received: September 10, 2010
Last updated: December 8, 2014
Last verified: August 2014
Results First Received: December 8, 2014  
Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Condition: Metastatic Breast Cancer
Interventions: Drug: Abraxane
Drug: Carboplatin

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Abraxane, Carboplatin

Abraxane 100mg/m2 IV days 1, 8 and 15 of a 28 day cycle Carboplatin area under the concentration curve, (AUC)2 IV days 1,8, and 15 of a 28 day Cycle

Abraxane: Abraxane® 100 mg/m2 IV over 30 min days 1,8,15 every 28 days

Carboplatin: area under curve(AUC)=2 over 15 minutes days 1,8,15 every 28 days


Participant Flow:   Overall Study
    Abraxane, Carboplatin  
STARTED     10  
COMPLETED     0  
NOT COMPLETED     10  
Withdrawal by Subject                 5  
Adverse Event                 2  
progression                 2  
Withdrawal by Treating Physician                 1  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Abraxane, Carboplatin

Abraxane 100mg/m2 IV days 1, 8 and 15 of a 28 day cycle Carboplatin area under the concentration curve, (AUC)2 IV days 1,8, and 15 of a 28 day Cycle

Abraxane: Abraxane® 100 mg/m2 IV over 30 min days 1,8,15 every 28 days

Carboplatin: area under curve(AUC)=2 over 15 minutes days 1,8,15 every 28 days


Baseline Measures
    Abraxane, Carboplatin  
Number of Participants  
[units: participants]
  10  
Age  
[units: participants]
 
<=18 years     0  
Between 18 and 65 years     9  
>=65 years     1  
Age  
[units: years]
Mean (Standard Deviation)
  54.5  (8.1)  
Gender  
[units: participants]
 
Female     10  
Male     0  
Race (NIH/OMB)  
[units: participants]
 
American Indian or Alaska Native     0  
Asian     7  
Native Hawaiian or Other Pacific Islander     0  
Black or African American     1  
White     2  
More than one race     0  
Unknown or Not Reported     0  
Region of Enrollment  
[units: participants]
 
United States     3  
China     7  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   PFS   [ Time Frame: PFS is defined as the interval from study registration to disease progression or death due to any cause, whichever comes first ]

2.  Secondary:   To Assess the Safety and Tolerability of a Combination Regimen of Weekly Abraxane® and Carboplatin to Treat Women With "Triple Negative" Stage IV Metastatic Breast Cancer   [ Time Frame: 2 years ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Results Point of Contact:  
Name/Title: Dr Kimberly Blackwell
Organization: Duke University Medical Center
phone: 919-6681748
e-mail: black034@mc.duke.edu


No publications provided


Responsible Party: Duke University
ClinicalTrials.gov Identifier: NCT01207102     History of Changes
Other Study ID Numbers: Pro00019321
Study First Received: September 10, 2010
Results First Received: December 8, 2014
Last Updated: December 8, 2014
Health Authority: United States: Institutional Review Board